ABBV Sep 2020 57.500 put

OPR - OPR Delayed Price. Currency in USD
0.8000
0.0000 (0.00%)
As of 3:59PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.8000
Open0.8000
Bid0.6600
Ask0.8400
Strike57.50
Expire Date2020-09-18
Day's Range0.8000 - 0.8000
Contract RangeN/A
Volume2
Open Interest50
  • 3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019 (Revised)
    Zacks

    3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019 (Revised)

    Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

  • Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019 (Revised)
    Zacks

    Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019 (Revised)

    Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

  • Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020
    Investor's Business Daily

    Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020

    Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

  • 5 Cheap Dividend Stocks With High Yields And Annual Increases
    InvestorPlace

    5 Cheap Dividend Stocks With High Yields And Annual Increases

    When writing this article, I was looking for an ideal list of dividend-paying stocks that consistently raise their dividends each year. In addition, the dividend yields have to be higher than average. I used a cutoff of 4 to 6% dividend yield.This is much higher than the S&P 500, with its dividend yield of 1.8%. So picking these stocks has a good chance of appreciation.The stocks also have to be cheap. The price-to-earnings ratio hurdle to make my list is 11 times or lower. This is significantly lower than most stocks trading today. For example, the S&P 500 P/E ratio is 23.8 times earnings. On a forward basis, it is slightly below 20x. So my cutoff is almost 50% to 60% of the market average.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Worst Dividend Stocks of the Decade Lastly, the company has to be able to afford the dividends. Earnings per share must be higher than the dividend per share.Even with as strict as all that may sound, I still found five stocks that met these criteria in spades. You might consider investing in them. Dividend Stocks to Buy: AT&T (T)Dividend Yield: 5.3%Price-to-Earnings Ratio: 10.8xAverage Dividend Growth Over 5 Years: 2%Source: Mark R. Hake AT&T (NYSE:T) has consistently raised its dividends to shareholders each year. You can see this in the chart I prepared, at right. Dividends per share are growing consistently by 2% or higher each year over the past three to five years.In addition, AT&T is very cheap compared to its earnings per share. The P/E ratio is below 11x.AT&T purchased Time Warner a little over a year ago and is still in the process of integrating the company. Analysts expect earnings to grow by 2.2% in 2020. Moreover, this is also the same amount by which dividends are expected to grow next year.T stock is expected to begin buying back shares on a larger scale. I recently wrote an article about this which you can read here. Moreover, earnings cover T stock dividend very well. The $2.05 dividend rate represents just 57% of its expected $3.55 earnings per share. AbbVie (ABBV)Dividend Yield: 5.3%Price-to-Earnings Ratio: 9.9xAverage Dividend Growth Over 5 years: 21%AbbVie is a $128 billion market value drug manufacturing company. It has consistently raised its dividend over the past five years. You can see this in the chart I have prepared. On average dividends have increased by 21% per year.Source: Mark R. Hake In addition, ABBV stock is very cheap. For example, International Business Machines (NYSE:IBM) stock trades for less than 10 times earnings. In 2020, expected earnings of $9.91 per share put ABBV stock at a P/E of 8.75 times.Abbie made a cash and stock bid for Allergan (NYSE:AGN) in late June 2019. AGN is a $61 billion market cap U.K./U.S. drug company. The deal is expected to close in early 2020. AbbVie claims the deal will significantly increase shareholder value.As it stands, the dividend per share for ABBV stock is well covered by its earnings. The annual $4.72 dividend per share represents just 53% of expected earnings of $8.93 per share. * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 In sum, ABBV stock looks like a good cheap, high-yield and consistent dividend-paying stock worth buying. Dividend Stocks to Buy: Harley-Davidson (HOG)Dividend Yield: 3.9%Price-to-Earnings Ratio: 11.6xAverage Dividend Growth Over 5 Years: 11.99%Harley-Davidson (NYSE:HOG) stock has a very nice dividend yield of 3.9%. The company has had a rough few years from EU and China tariffs. Nevertheless, HOG has paid consistently higher dividends, as can be seen in the chart. Its average dividend growth has been 12% over the past five years.Source: Mark R. Hake HOG stock presently trades on 11.6 times earnings. The company is experiencing lower earnings from the tariffs and lower bike sales as a result. Nevertheless, it has reduced its costs. Revenue next year is expected to be slightly higher than this year.Earnings for 2020 are expected to be $3.55 per share by analysts covered by Seeking Alpha. That puts HOG stock at less than 11x earnings.The dividend per share of $1.50 is well covered by expected earnings. Once the tariffs are lifted, HOG stock has a good chance of increasing earnings and dividends dramatically.Meanwhile, the dividend yield of almost 4% is a good inducement for investors to wait for things to turn around for Harley-Davidson. International Business Machines (IBM)Dividend Yield: 4.8%Price-to-Earnings: 10.6xAverage Dividend Growth 5 Years: 10.91%IBM has consistently raised its dividend per share over the past 5 years. Its average dividend growth has been stellar at 10.9%. You can see this in the chart at the right.Source: Mark R. Hake In addition, IBM is very cheap. It trades at just 10.6 times earnings. In 2020 EPS is expected to be $13.31 per share, according to Seeking Alpha. This puts IBM stock on just 10x forward earnings.Moreover, IBM's $6.48 dividend per share is just over 50% of the EPS of $12.80 or so expected this year. As a result, you can see the earnings well cover the dividend.I have written several articles on IBM and its push into the hybrid cloud space now that it fully owns Red Hat. IBM paid $34 billion for that acquisition, which closed in early July 2019. IBN believes the hybrid cloud market represents a $1.2 trillion opportunity over the next decade. Most companies will need to move their operations onto the cloud over that period. * 7 Earnings Reports to Watch Next Week This bodes well for IBM over the long run. With its 4.8% dividend yield, IBM stock will pay investors to investors to wait for earnings to take advantage of the expected spike from hybrid cloud growth. Kohl's Corp (KSS)Dividend Yield: 5.5%Price-to-Earnings: 10.3xAverage Dividend Growth 5 Years: 11.4%Kohl's (NYSE:KSS), the department store chain, can catch your eye with a very nice dividend yield of 5.5%. Moreover, KSS has increased its dividend annually on average 11.4% over the past five years.EPS is expected to be $4.77 this year. Therefore KSS's earnings well cover the dividends. Dividends take up just 56% of earnings. In addition, next year EPS is expected to be roughly flat with this year, according to Seeking Alpha.KSS stock trades for about 10 times earnings. KSS stock is very cheap at these prices. For example, several reasons for this relate to tariff headwinds and customers' increasing preference to shop online. Its recent deal to take in Amazon returns will help drive traffic to its physical stores.I believe that Kohl's will be a winner in the omnichannel sales space. At this price, which is very cheap, the dividend pays investors very well to wait for the company to grow earnings.As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Mark Hake runs the Total Yield Value Guide which you can review here. The Guide focuses on high total yield value stocks. This includes both high dividend and buyback yield stocks. In addition, subscribers a two-week free trial. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade * 7 Tech Stocks to Stuff Your Stocking With * 7 Sinfully Good Casino Stocks That Could Win the Jackpot in 2020 The post 5 Cheap Dividend Stocks With High Yields And Annual Increases appeared first on InvestorPlace.

  • Retirees Should Know These 3 Facts About Required Minimum Distributions - December 13, 2019
    Zacks

    Retirees Should Know These 3 Facts About Required Minimum Distributions - December 13, 2019

    Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

  • Barrons.com

    Walgreens, AbbVie, and 3 Other Dividend Aristocrat Stocks That Have Lagged the Market This Year

    The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. For example, in last year’s tumultuous fourth quarter, with the S&P 500 down 13.5%, the Aristocrats fell 8.6%. 2019 has hardly been tough for stocks, with the S&P 500 having returned about 26%.

  • Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal
    GuruFocus.com

    Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal

    Needham analyst raises target price after promising results of drug trial Continue reading...

  • AbbVie's 2019 Points to the End of the Efficient Market Thesis - Cramer

    Jim Cramer sees the market's reaction to AbbVie's purchase of Allergan as an example of its move away from valuing fundamentals and instead getting bogged down in the noise.

  • The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
    Zacks

    The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America

    The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America

  • 3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019
    Zacks

    3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019

    Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

  • Should We Worry About AbbVie Inc.'s (NYSE:ABBV) P/E Ratio?
    Simply Wall St.

    Should We Worry About AbbVie Inc.'s (NYSE:ABBV) P/E Ratio?

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...

  • Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019
    Zacks

    Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019

    Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

  • Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
    Zacks

    Vertex's Kalydeco Gets EU Approval to Treat CF in Infants

    Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.

  • Top Research Reports for Novartis, AbbVie & Sanofi
    Zacks

    Top Research Reports for Novartis, AbbVie & Sanofi

    Top Research Reports for Novartis, AbbVie & Sanofi

  • Biotech ETFs Hit New Highs on Deal Activities
    Zacks

    Biotech ETFs Hit New Highs on Deal Activities

    Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

  • Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?
    Investor's Business Daily

    Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?

    Merck stock is on an upswing with a 14% gain in the first 11 full months of 2019. Meanwhile shares of other pharma companies grabbed a smaller gain. Is it time to give MRK stock a shot?

  • AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
    Zacks

    AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    In the latest trading session, AbbVie (ABBV) closed at $86.43, marking a -0.63% move from the previous day.

  • J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
    Zacks

    J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

    J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.

  • World's largest biotech company to move up to BioMed's big South City project
    American City Business Journals

    World's largest biotech company to move up to BioMed's big South City project

    The biotech company acquired its first Bay Area presence 15 years ago; now it's planning to move into a high-profile biotech-focused project.

  • Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
    Zacks

    Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

    Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.

  • 3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019
    Zacks

    3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019

    The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

  • GlobeNewswire

    Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

    Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.

  • PR Newswire

    AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.

  • PR Newswire

    New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combination with rituximab (VenR) in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). The updated data from the Phase 3 MURANO trial four-year analysis (median follow-up of 48 months with all patients off VENCLEXTA/VENCLYXTO treatment for a median of 22 months) showed that patients with R/R CLL who completed the chemotherapy-free, two-year fixed duration course of VENCLEXTA/VENCLYXTO treatment combination maintained progression-free survival (PFS) and overall survival (OS). Patients who completed treatment with the VENCLEXTA/VENCLYXTO combination also achieved higher rates of minimal residual disease (MRD)-negativity and complete remissions compared to those treated with a standard of care, bendamustine plus rituximab (BR).1 The full results were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (abstract 355).

  • PR Newswire

    More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA® (ibrutinib) monotherapy compared to later lines of therapy (LOT) extended progression-free survival (PFS) and increased the likelihood of a complete response (CR) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) – demonstrating that some patients achieved a disappearance of any signs of disease.